Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study

Q3 Medicine

Cephalalgia Reports Pub Date : 2024-01-01 DOI:10.1177/25158163241238448

Hsiangkuo Yuan, Fred Cohen, Maurice T. Driessen, L. Krasenbaum, Mario Ortega, Mary Hopkins, M. Marmura

{"title":"Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study","authors":"Hsiangkuo Yuan, Fred Cohen, Maurice T. Driessen, L. Krasenbaum, Mario Ortega, Mary Hopkins, M. Marmura","doi":"10.1177/25158163241238448","DOIUrl":null,"url":null,"abstract":"Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM). This was a single-center, retrospective, observational study that assessed treatment response (change over time in monthly headache days [MHD] and pain intensity [PI]) in adult patients with CM receiving fremanezumab as add-on therapy to onabotA for CM prevention. In the study population ( N = 116, age 50.0 ± 13.1, female 85.3%, pre-index onabotA use 46.5 ± 34.2 months) receiving concurrent onabotA and fremanezumab for 17.5 ± 11.6 months, MHD decreased by 3.60 days (95% confidence interval [CI]: −5.26, −1.94, p < 0.001) and PI was reduced by 0.43 (95% CI: −0.77, −0.09, p = 0.012) at the final visit. Statistically significant reductions were seen in both MHD (−4.61, 95% CI: −6.84, −2.39; p < 0.001) and PI (−0.52, 95% CI: −0.84. −0.09; p = 0.017) among patients naïve to mAbs against CGRP or its receptor. No unexpected adverse events were observed. Concomitant fremanezumab and onabotA for CM prevention were effective at reducing the number of MHD and lessening PI, particularly in patients with difficult-to-treat CM who are naïve to mAbs against CGRP or its receptor.","PeriodicalId":9702,"journal":{"name":"Cephalalgia Reports","volume":"131 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cephalalgia Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25158163241238448","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Concomitant fremanezumab, a calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), and onabotulinumtoxinA (onabotA) improve treatment response compared with onabotA alone in patients with chronic migraine (CM). This was a single-center, retrospective, observational study that assessed treatment response (change over time in monthly headache days [MHD] and pain intensity [PI]) in adult patients with CM receiving fremanezumab as add-on therapy to onabotA for CM prevention. In the study population ( N = 116, age 50.0 ± 13.1, female 85.3%, pre-index onabotA use 46.5 ± 34.2 months) receiving concurrent onabotA and fremanezumab for 17.5 ± 11.6 months, MHD decreased by 3.60 days (95% confidence interval [CI]: −5.26, −1.94, p < 0.001) and PI was reduced by 0.43 (95% CI: −0.77, −0.09, p = 0.012) at the final visit. Statistically significant reductions were seen in both MHD (−4.61, 95% CI: −6.84, −2.39; p < 0.001) and PI (−0.52, 95% CI: −0.84. −0.09; p = 0.017) among patients naïve to mAbs against CGRP or its receptor. No unexpected adverse events were observed. Concomitant fremanezumab and onabotA for CM prevention were effective at reducing the number of MHD and lessening PI, particularly in patients with difficult-to-treat CM who are naïve to mAbs against CGRP or its receptor.

查看原文本刊更多论文

美国一家三级头痛中心对接受奥那博定注射液（onabotulinumtoxinA）预防慢性偏头痛的患者加用氟马尼珠单抗的实际效果：回顾性图表研究

在慢性偏头痛（CM）患者中，降钙素基因相关肽（CGRP）通路单克隆抗体（mAb）和奥那博定（onabotulinumtoxinA，onabotA）同时使用可改善治疗反应，而单独使用奥那博定可改善治疗反应。这是一项单中心、回顾性、观察性研究，目的是评估接受fremanezumab治疗的成年偏头痛患者的治疗反应（每月头痛天数[MHD]和疼痛强度[PI]随时间的变化）。在研究人群（N = 116，年龄 50.0 ± 13.1，女性 85.3%，使用奥那博特前指数 46.5 ± 34.2 个月）中，同时接受奥那博特和氟马尼珠单抗治疗 17.5 ± 11.6 个月后，最终就诊时，MHD 减少了 3.60 天（95% 置信区间 [CI]：-5.26, -1.94, p < 0.001），PI 减少了 0.43（95% 置信区间：-0.77, -0.09, p = 0.012）。在未使用抗 CGRP 或其受体 mAbs 的患者中，MHD（-4.61，95% CI：-6.84，-2.39；p <0.001）和 PI（-0.52，95% CI：-0.84，-0.09；p = 0.017）均有统计学意义的明显降低。未观察到意外不良事件。同时使用fremanezumab和onabotA预防CM能有效减少MHD的数量并降低PI，特别是对于那些对抗CGRP或其受体的mAbs不敏感、难以治疗的CM患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cephalalgia Reports Medicine-Neurology (clinical)

CiteScore

2.50

自引率

0.00%

发文量

审稿时长

9 weeks